Edition:
United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

0.66USD
12:54pm EST
Change (% chg)

$0.02 (+2.87%)
Prev Close
$0.64
Open
$0.64
Day's High
$0.68
Day's Low
$0.64
Volume
14,373
Avg. Vol
16,162
52-wk High
$2.03
52-wk Low
$0.62

CLSN.OQ

Chart for CLSN.OQ

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $16.73
Shares Outstanding(Mil.): 26.08
Dividend: --
Yield (%): --

Financials

  CLSN.OQ Industry Sector
P/E (TTM): -- 40.79 30.35
EPS (TTM): -0.90 -- --
ROI: -60.80 -0.56 15.27
ROE: -124.36 -1.20 16.60

BRIEF-Celsion provides update on immunotherapy study in ovarian cancer patients

* Celsion announces continuing positive data from the ovation study - an immunotherapy study of newly diagnosed stage iii and iv ovarian cancer patients

Nov 10 2016

BRIEF-Celsion Corp reports Q3 loss per share $0.23

* Celsion corporation reports third quarter 2016 financial results and provides business update

Nov 10 2016

BRIEF-Celsion files for resale of up to 8.8 mln shares of co's common stock

* Files for resale of up to 8.8 million shares of co's common stock by selling stockholders - SEC filing Source text for Eikon: [http://bit.ly/2dWdFbl] Further company coverage:

Oct 31 2016

BRIEF-Celsion corp gets positive DSMB review of Phase Ib ovation study

* Says future studies of GEN-1 will include a phase I/II study combining GEN-1 with avastin and doxil

Sep 15 2016

BRIEF-Zhejiang Hisun Pharma signs agreement with U.S.-based Celsion Corp

* Says it signs agreement on technology transfer, production and products supply with Celsion Corp

Aug 16 2016

BRIEF-Celsion posts Q2 loss of $0.19/share

* Celsion Corporation reports second quarter 2016 financial results and provides business update

Aug 15 2016

BRIEF-Celsion announces final overall survival data from HEAT study of ThermoDox in primary liver cancer

* Median overall survival for ThermoDox group reached which translates into two year survival benefit over optimized RFA only group

Aug 15 2016

BRIEF-Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy

* Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy

Aug 09 2016

BRIEF-Celsion Corp says updates on OVATION study

* Celsion Corp says announces positive data from OVATION study Source text for Eikon: Further company coverage:

Jul 25 2016

BRIEF-Celsion Corp announces $6 mln registered direct offering

* Celsion corporation announces $6 million registered direct offering

Jun 13 2016

Competitors

Earnings vs. Estimates